In situ activation of Car T cells for therapy
Traditional CAR T therapy requires specialized production facilities to isolate, activate, modify, and to expand in vitro the engineered cells before transfusion back into patients. This level of individualized manufacturing is expensive and restricts application of this specialized therapy socioeconomically and geographically. Mayo Clinic seeks to provide a cheaper, off-the-shelf alternative designed to make CAR T therapy faster and more widely available to patients.
Our innovative approach generates in situ CAR T cells using an activation protocol shown to promote T cells capable of immune surveillance of non-inflamed tissues followed by identification and destruction of antigen positive cells. The T cells activated in situ have superior ability to search out and destroy antigen positive cells in comparison to T cells activated using CAR T manufacturing protocols in vitro.